DCDaniel Candotti

Daniel Candotti

*This is an algorithmically generated author record based on publicly available information.

Daniel Candotti has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Specific Amino Acid Substitutions in the S Protein Prevent Its Excretion In Vitro and May Contribute to Occult Hepatitis B Virus Infection

    by Subhajit Biswas, Daniel Candotti, Jean-Pierre Allain

    Occult hepatitis B virus (HBV) infection (OBI) is defined as low plasma level of HBV DNA with undetectable HBV surface antigen (HBsAg) outside the preseroconversion window period. The mechanisms leading to OBI remain largely unknown. The potential role of specific amino acid substitutions in the S protein from OBI in HBsAg production and excretion was examined in vitro . HBsAg was quantified in culture supernatants and cell extracts of HuH-7 cells transiently transfected with plasmids containing the S gene of eight HBsAg + controls and 18 OBI clones. The intracellular (IC)/extracellular (EC) HBsAg production ratio was ∼1.0 for the majority of controls. Three IC/EC HBsAg patterns were observed in OBI strains clones: pattern 1, an IC/EC ratio of 1.0, was found in 5/18 OBI clones, pattern 2, detectable IC but low or undetectable EC HBsAg (IC/EC, 7.0 to 800), was found in 6/18 OBIs, and pattern 3, low or undetectable IC and EC HBsAg, was found in 7/18 clones. Intracellular immunofluorescence staining showed that in pattern 2, HBsAg was concentrated around the nucleus, suggesting retention in the endoplasmic reticulum. The substitution M75T, Y100S, or P178R was present in 4/6 pattern 2 OBI clones. Site-directed-mutagenesis-corrected mutations reversed HBsAg excretion to pattern 1 and, when introduced into a control clone, induced pattern 2 except for Y100S. In a control and several OBIs, variants of a given quasispecies expressed HBsAg according to different patterns. However, the P178R substitution present in all cloned sequences of two OBI strains may contribute significantly to the OBI phenotype.


  • Molecular virology in transfusion medicine laboratory

    by Daniel Candotti, Jean-Pierre Allain


  • Transfusion transmission of hepatitis B virus: still learning more about it

    by D. Candotti, M. El Chaar, J.‐P. Allain

    Background  Despite continuous technical improvement in blood donation testing, hepatitis B infection remains a major risk of transfusion‐transmitted viral infection. The residual risk of hepatitis B virus (HBV) transmission is related to the pre‐seroconversion window period (WP), infection with immunovariant viruses, and with occult carriage of HBV infection (OBI).Results and discussion  Reduction of HBV residual risk is achieved by developing more sensitive HBsAg test, by adopting anti‐HBc screening when appropriate, and recently by implementing HBV nucleic acid testing (NAT), either in minipools or more efficiently in individual donations. Compared with serological testing, HBV NAT combines the ability to significantly reduce the window period and to detect OBIs. Clinical observations suggest lower transmission rate of occult HBV than WP. Lower transmission rate might be related to the low viral load generally observed in OBI donors or to the presence of defective variants associated with occult carriage. In addition, there is evidence that OBI‐infected donors carrying neutralizing anti‐HBs (∼50%) are unlikely to be infectious, while those with anti‐HBc only may be more infectious especially in immunocompromised recipients. Immunodeficient elderly and patients receiving immunosuppressive treatments (organ transplantation or cancer chemotherapy) may be susceptible to infection with lower infectious dose even in the presence of anti‐HBs. There is no evidence that blood from anti‐HBc only positive/HBV DNA‐negative donors is infectious. Present evidence suggests that the association of HBsAg and sensitive NAT screening adequately covers risks of HBV transfusion–transmission, allowing to dispense or discontinue anti‐HBc screening, avoiding discarding non‐infectious and precious blood units, particularly in high prevalence areas. Identification of ‘post‐transfusion’ HBV infection relies essentially on clinical evidence of acute infection or on look‐back exercises following the identification of HBV DNA‐positive donations. To protect from HBV infection the increasing number of immunodeficient recipients, maximum sensitivity of HBV NAT is required. As these recipients are also at risk of viral reactivation when previously exposed, anti‐HBc testing and storage of a pre‐transfusion sample when anti‐HBc‐positive would prevent the difficulties of differentiating between transfusion–transmission and reactivation.


  • Open Access

    Transfusion-transmitted hepatitis B virus infection

    by Daniel Candotti, Jean-Pierre Allain


  • Maternofetal transmission of hepatitis B virus genotype E in Ghana, west Africa

    by Daniel Candotti, Kwabena Danso, Jean-Pierre Allain

    To determine whether maternofetal transmission of hepatitis B virus (HBV) is a common route of infection leading to chronic infection in west Africa, plasma samples, obtained at delivery from 1368 pregnant Ghanaian women and paired umbilical cord blood or newborn whole blood samples, were tested for HBV surface antigen (HBsAg) and DNA. A 16 % prevalence of HBV chronic carriers, defined as detectable HBsAg and/or HBV DNA, was found, >80 % contained less than 1×104 IU ml−1 HBV DNA and 99 % were infected with genotype E strains. HBV maternofetal transmission was documented in 17 out of 204 (8.3 %) paired HBV carrier women–cord blood/newborn samples. The rate of transmission was 55 % and 3.3 % when maternal viral load was above or below 1×104 IU ml−1, respectively (P=0.0008). Maternofetal transmission of HBV genotype E was estimated to account for 8 % of the cases of chronic HBsAg carriers. Six women with low viral load at delivery (five −1) and anti-HBe (hepatitis B e antigen) transmitted HBV. Surprisingly, while non-transmitted low viral load strains had 79 % mutations at position 1896 of HBV genome, transmitted strains were all wild-type despite anti-HBe presence (P=0.0041), suggesting the possible role of HBeAg as risk factor for HBV maternofetal transmission. The relative risk of maternofetal transmission was 2.4 when pregnant women carried high viral load and 11.5 when carrying wild-type strains at position 1896, irrespective of viral load. We conclude that viral load and pre-core wild-type at position 1896 are two independent risk factors for HBV genotype E maternofetal transmission, which remains a minor contributor to high prevalence of chronic infection.


    • 1 January 2007
      • Vol. 127, 71-86

    The utility of multiplex NAT in blood screening.

    by D Candotti, J P Allain


  • Open Access

    Maternal‐Fetal Transmission of Human Parvovirus B19 Genotype 3

    by Daniel Candotti, Kwabena Danso, Armen Parsyan, Albert Dompreh, Jean‐Pierre Allain

    Plasma samples obtained at delivery from 885 pregnant Ghanaian women were tested for human parvovirus B19 DNA and B19-specific antibodies. Maternal-fetal transmission was evaluated by testing paired maternal plasma and umbilical cord blood samples, as well as newborn whole-blood samples when they were available. The B19 DNA seroprevalence rate in women was 1.8% (94% had genotype 3 strains), and the immunoglobulin G (IgG) seroprevalence rate in women was 81%. Two of 3 cases of primary maternal B19 infection resulted in fetal transmission. Coexistence of B19 DNA and B19-specific IgG (persistence) was detected in 13 women (1.5%), but no transmission of the virus was observed. Contrary to the situation in pregnant women with primary B19 infection and high viral loads, pregnant women with low viral loads and B19-specific IgG do not appear to be vertically infectious


  • Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase

    by D. Candotti, O. Opare-Sem, H. Rezvan, F. Sarkodie, J.-P. Allain

    Summary. Candidate blood donors in Ghana are frequent carriers of hepatitis B virus (HBV). A comparative study of 117 donor samples including 46 with alanine aminotransferase (ALT) ≥ 60 IU/L and 71 with ≤40 IU/L level was undertaken. S and the basic core promoter-precore regions (BCP/PC) sequencing was used to identify genotypes and variants relevant to HBV natural history, respectively. Age, viral load, HBe status were correlated with molecular data. HBV genotype E (87%) was dominant with little genotypes A (10%) and D (3%). Comparing individuals with or without liver disease, an association between liver disease and older age (P = 0.004) and higher viral load (P = 0.002) whether as a whole population or only genotype E was found. Compared with a commercial assay, BCP/PC sequencing had lower sensitivity to detect mixtures of wild-type and variant viruses but detected BCP deletions. BCP 1762/1764 variants were positively correlated with older age (P < 0.0001) and elevated ALT levels (P = 0.01). PC 1896 stop codon was marginally correlated with viral load (P = 0.09). HBV genotype E infection natural history appears different from genotypes B and C prevalent in Asia. Donors with liver disease being older, with higher viral load and higher BCP variant proportion may be at higher risk of cirrhosis and hepatocellular carcinoma